would there be different effects in the different cell types what are the differences in mixing volume and soma the adme profile of nanoparticles versus larger particles what preclinical screening tests would be useful to identify potential risks in vitro or in vivo can new technologies such as omics help identify potential toxicities acetaminophen caffeine and dihydrocodeine bitartrate and how can these methodologies complement current testing requirements can nanoparticles gain access to the systemic circulation from the route of exposure?